Morgan Preziosi, Satdarshan P. Monga – 9 May 2018

John E. Eaton, Mette Vesterhus, Bryan M. McCauley, Elizabeth J. Atkinson, Erik M. Schlicht, Brian D. Juran, Andrea A. Gossard, Nicholas F. LaRusso, Gregory J. Gores, Tom H. Karlsen, Konstantinos N. Lazaridis – 9 May 2018 – Improved methods are needed to risk stratify and predict outcomes in patients with primary sclerosing cholangitis (PSC). Therefore, we sought to derive and validate a prediction model and compare its performance to existing surrogate markers.

Emily K. Butler, Jeffrey Gersch, Anne McNamara, Ka‐Cheung Luk, Vera Holzmayer, Maria de Medina, Eugene Schiff, Mary Kuhns, Gavin A. Cloherty – 7 May 2018 – Treatment of chronic hepatitis B (CHB) patients with nucleos(t)ide analogs (NAs) suppresses hepatitis B virus (HBV) DNA synthesis but does not affect synthesis of HBV pregenomic RNA (pgRNA). Hepatitis B virus pgRNA is detectable in the serum during NA treatment and has been proposed as a marker of HBV covalently closed circular DNA activity within the infected hepatocyte.

Yuanjie Pang, Christiana Kartsonaki, Iain Turnbull, Yu Guo, Robert Clarke, Yiping Chen, Fiona Bragg, Ling Yang, Zheng Bian, Iona Y. Millwood, Juanzhi Hao, Xianyong Han, Yajing Zang, Junshi Chen, Liming Li, Michael V. Holmes, Zhengming Chen – 7 May 2018 – The prevalence of diabetes is increasing rapidly in China. However, evidence is limited about its effects on chronic liver diseases and liver cancer.

Nora Winkler, Felix Strübing, Wolfgang Groß, Walter Mier, Eduard Ryschich – 7 May 2018 – The systemic drug circulation represents a source of adverse effects during tumor targeting. We studied the binding efficacy of endothelium‐specific antibodies after a very short contact with an antigen target, along with assessing the intravascular capture and targeting potential of these antibodies after locoregional injection. Fast‐binding anti–CD 146 (clone ME‐9F1) and anti‐CD31 (clone 390) antibodies were selected based on histological analysis of their binding activity.

Yuanjie Pang, Christiana Kartsonaki, Iain Turnbull, Yu Guo, Robert Clarke, Yiping Chen, Fiona Bragg, Ling Yang, Zheng Bian, Iona Y. Millwood, Juanzhi Hao, Xianyong Han, Yajing Zang, Junshi Chen, Liming Li, Michael V. Holmes, Zhengming Chen – 7 May 2018 – The prevalence of diabetes is increasing rapidly in China. However, evidence is limited about its effects on chronic liver diseases and liver cancer.

Keiichi Fujiwara, Shin Yasui, Osamu Yokosuka, Shigeto Oda, Naoya Kato – 7 May 2018

Sarah Raevens, Michael B. Fallon – 5 May 2018 – Hepatopulmonary syndrome (HPS) is a relatively common and potentially severe pulmonary complication of cirrhosis with increased risk of mortality. In experimental models, a complex interaction between pulmonary endothelial cells, monocytes, and the respiratory epithelium, which produces chemokines, cytokines, and angiogenic growth factors, causes alterations in the alveolar microvasculature, resulting in impaired oxygenation.

Theodore H. Welling, Kevin Eddinger, Kristen Carrier, Danting Zhu, Tyler Kleaveland, Derek E. Moore, Douglas E. Schaubel, Peter L. Abt – 5 May 2018 – Orthotopic liver transplantation (OLT) and resection are effective treatments for hepatocellular carcinoma (HCC). However, optimizing OLT and limiting HCC recurrence remains a vexing problem. New HCC Model for End‐Stage Liver Disease and allocation algorithms provide greater observation of HCC patients, many while receiving local‐regional treatments.

Huixia Zhang, Chao Zhang, Hong Tang, Shanshan Gao, Fang Sun, Yuan Yang, Weiping Zhou, Yu Hu, Changshu Ke, Yu Wu, Zeyang Ding, Lin Guo, Rongjuan Pei, Xinwen Chen, Man‐Sun Sy, Bixiang Zhang, Chaoyang Li – 5 May 2018 – Chronic hepatitis C virus (HCV) infection can result in steatosis, a condition displaying aberrant accumulation of neutral lipid vesicles, the component of lipid droplets (LDs), which are essential for HCV assembly. However, the interplay between HCV infection and steatosis remains unclear.